| REGULATORY | regulatory | OZEMPIC — FDA prescribing information | FDA | — | 2026-01-30 |
| REGULATORY | regulatory | D-0245-2026 — Wegovy (semaglutide) Injection, 1 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC 0169-4501-14 | FDA | — | 2025-12-19 |
| REGULATORY | regulatory | D-0244-2026 — Wegovy (semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880 Bagsvaerd, Denmark, Product of Denmark, Novo Nordisk A/S, Novo Nordisk Inc., Plainsboro, NJ 08536, NDC 0169-4505-14 | FDA | — | 2025-12-19 |
| REGULATORY | regulatory | D-0119-2026 — Semaglutide Injection, 5 mg/2 mL (2.5 mg/mL), 2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-02 | FDA | — | 2025-10-15 |
| REGULATORY | regulatory | D-0114-2026 — Semaglutide Injection, 12.5/5mL (2.5 mg/mL), 5mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09 | FDA | — | 2025-10-15 |
| REGULATORY | regulatory | D-0117-2026 — Semaglutide Injection, 8mg/3.2mL (2.5 mg/mL), 3.2mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-09 | FDA | — | 2025-10-15 |
| REGULATORY | regulatory | D-0118-2026 — Semaglutide Injection, 2.5mg/1mL (2.5 mg/mL), 1mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-06 | FDA | — | 2025-10-15 |
| REGULATORY | regulatory | D-0115-2026 — Semaglutide Injection, 10 mg/4 mL (2.5 mg/mL), 4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-04 | FDA | — | 2025-10-15 |
| REGULATORY | regulatory | D-0116-2026 — Semaglutide Injection, 6mg/2.4mL (2.5 mg/mL), 2.4mL Multidose Vial, For Subcutaneous Use, Rx Only, Mfd by: ProRx, 619 Jeffers Cir, Exton, PA 19341. NDC: 84139-225-08 | FDA | — | 2025-10-15 |
| REGULATORY | regulatory | D-0091-2026 — Semaglutide for Injection, a) 20 mg b) 20 mg/mL, 10 mL Multi-Dose Vials, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. Also labeled as manufactured for Synergy Wellness, 20 mg, 10mL vial lyophilized. | FDA | — | 2025-07-30 |
| REGULATORY | regulatory | D-0083-2026 — Semaglutide with B12 for Injection, all strengths and presentations, GenoGenix, LLC, 2840 NW 2nd Ave Ste 204 Boca Raton, FL 33431-6692. | FDA | — | 2025-07-30 |
| REGULATORY | regulatory | D-0564-2025 — Semaglutide + Cyanocobalamin injection solution, 2.21 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. | FDA | — | 2025-07-18 |
| REGULATORY | regulatory | D-0561-2025 — Semaglutide + Cyanocobalamin 0.44 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. | FDA | — | 2025-07-18 |
| REGULATORY | regulatory | D-0553-2025 — Semaglutide + Cyanocobalamin 0.22 mg + 0.25mg/0.5 ml Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. | FDA | — | 2025-07-18 |
| REGULATORY | regulatory | D-0563-2025 — Semaglutide +Cyanocobalamin 1.5 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. | FDA | — | 2025-07-18 |
| REGULATORY | regulatory | D-0562-2025 — Semaglutide + Cyanocobalamin 0.88 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. | FDA | — | 2025-07-18 |
| REGULATORY | regulatory | D-0565-2025 — Semaglutide + Cyanocobalamin 2.67 mg + 0.25mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, 2 mL Multi Dose Vial, Refrigerate, Do not freeze, Aequita Pharmacy LLC, Kirkland, WA 98034. | FDA | — | 2025-07-18 |
| REGULATORY | regulatory | D-0609-2025 — Semaglutide, 2.5 mg/mL injection, 4 mL, Boothwyn Pharmacy | FDA | — | 2025-07-09 |
| REGULATORY | regulatory | D-0608-2025 — Semaglutide, 2.5 mg/mL injection, 0.8 mL, Boothwyn Pharmacy | FDA | — | 2025-07-09 |
| REGULATORY | regulatory | D-0606-2025 — Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy | FDA | — | 2025-07-09 |
| REGULATORY | regulatory | D-0480-2025 — Semaglutide, 5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | FDA | — | 2025-05-21 |
| REGULATORY | regulatory | D-0479-2025 — Semaglutide, 2.5 mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | FDA | — | 2025-05-21 |
| REGULATORY | regulatory | D-0481-2025 — Semaglutide/Cyanocobalamin Injectable, 5mg/1mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewood, CO 80112 | FDA | — | 2025-05-21 |
| REGULATORY | regulatory | D-0393-2025 — Wegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx Only, Single-Dose Only, Novo Nordisk Inc., Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, DK-2880, Bagsvaerd, Denmark, NDC 0169-4524-14. | FDA | — | 2025-04-09 |
| REGULATORY | regulatory | D-0654-2024 — Semaglutide / Cyanocobalamin Injection: 2.5/0.5 mg/mL, 2 mL Multiple Dose Vial, Compounded Rx Product, ProRX 267-565-7008, NDC 84139-225-02 | FDA | — | 2024-08-22 |
| REGULATORY | regulatory | D-0653-2024 — SEMAGLUTIDE 10mg/4mL (2.5mg/mL), 4 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-04 | FDA | — | 2024-08-22 |
| REGULATORY | regulatory | D-0652-2024 — SEMAGLUTIDE 5mg/2mL (2.5mg/mL), Rx Only 2 mL Multiple Dose Vial, Rx Only, Compounded Drug, Mfd by: ProRX Exton, PA19341, NDC 84139-225-01 | FDA | — | 2024-08-22 |
| REGULATORY | regulatory | D-0650-2024 — Semaglutide, 2 mL (2.5mg/mL), Compounded RX Product, Multidose SC inj, glass vial, ProRx, 267-565-7008, NDC 84139-225-01 | FDA | — | 2024-08-22 |
| REGULATORY | regulatory | WEGOVY — FDA prescribing information | FDA | — | 2024-04-23 |
| REGULATORY | regulatory | Ozempic — FDA prescribing information | FDA | — | 2023-11-22 |
| REGULATORY | regulatory | OZEMPIC — FDA prescribing information | FDA | — | 2023-11-17 |
| REGULATORY | regulatory | D-1105-2023 — Semaglutide/Cyanocobalamin 2mg/0.4mg/mL, 1mLvials, Tailor Made Compounding. | FDA | — | 2023-08-15 |
| REGULATORY | regulatory | D-0538-2023 — C-Semaglutide 5mg/mL injection, 0.5mL vials, Rx only, Vital Care Compounder 115 South 40th Ave, Suite A Hattiesburg, MS 39402 | FDA | — | 2023-04-13 |
| REGULATORY | regulatory | D-0236-2023 — SEMAGLUTIDE 0.5MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 1MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 2MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 4MG/ML (0.5ML VIAL) INJECTABLE SEMAGLUTIDE 5.4MG/ML (0.5ML VIAL) INJECTABLE, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA. | FDA | — | 2022-12-22 |
| REGULATORY | regulatory | D-0053-2023 — SEMAGLUTIDE INJECTION 5MG/ML (0.25MG/0.05ML) SOLN, various amounts in unit dose vials, Rx only, Vital Care Compounder, 115 S. 40th Ave., Hattiesburg, MS 39402 | FDA | — | 2022-10-07 |
| REGULATORY | regulatory | D-1520-2022 — Semaglutide/Cyanocobalamin 10/2 MG/ML Injectable, 0.4 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936. | FDA | — | 2022-08-26 |
| REGULATORY | regulatory | D-1519-2022 — Semaglutide/Cyanocobalamin 5/2 MG/ML Injectable, 0.2 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936. | FDA | — | 2022-08-26 |
| REGULATORY | regulatory | D-1521-2022 — Semaglutide/Cyanocobalamin 24/2 MG/ML Injectable, 0.4 ML syringe, Rx only, Carolina Infusion LLC, 95 Bees Creek Road, Ridgeland, SC 29936. | FDA | — | 2022-08-26 |
| REGULATORY | regulatory | D-1225-2022 — Semaglutide/Cyanocobalamin 5mg/0.2mg/ml, 2ml-vial, Refrigerate, Tailor Made Compounding | FDA | — | 2022-03-07 |
| REGULATORY | regulatory | D-1224-2022 — Semaglutide/Cyanocobalamin 2mg/0.4mg/ml, 1mL-vial, Refrigerate, Tailor Made Compounding | FDA | — | 2022-03-07 |
| REGULATORY | regulatory | D-0617-2021 — OZEMPIC (semaglutide) injection, 2 mg/1.5 mL (1.34 mg/mL) Prefilled pen, 1 pen, Sample. Not for Resale, Rx only, Novo Nordisk Inc, Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, Bagsvaerd, Denmark, NDC 0169-4132-90 (Pen), NDC 0169-4132-97 (Kit) | FDA | — | 2021-03-22 |
| REGULATORY | regulatory | D-0536-2021 — Rybelsus (semaglutide) Tablets 7 mg Once daily Each tablet contains 7 mg semaglutide 30 tablets 3 blister packs. Each pack contains 10 tablets. Rx only NDC 0169-4307-13 Manufactured by: Novo Nordisk A/S DK-2880 Bagsvaerd, Denmark | FDA | — | 2021-03-15 |
| REGULATORY | regulatory | OZEMPIC — FDA application NDA213051 | FDA | — | 2019-09-20 |
| ANIMAL | evidence | Semaglutide exerts anti-pulmonary fibrosis effects by inhibiting cellular senescence through activation of the Sirt1/HSF1/HSPs pathway. | Semaglutide | Longevity & cellular aging · animal | 2026-09-01 |
| ANIMAL | evidence | Semaglutide, at a dose that produces modest weight loss, induces mild suppression of bone remodeling in healthy control rats and those with chronic kidney disease. | Semaglutide | animal | 2026-09-01 |
| ANIMAL | evidence | Semaglutide treatment reverses HFD induced hippocampal microglia activation and improves cognitive dysfunction. | Semaglutide | Cognition & memory · animal | 2026-08-01 |
| ANIMAL | evidence | Chronic semaglutide alters ingestive behavior without impairing taste function in mice. | Semaglutide | Weight & fat loss · animal | 2026-08-01 |
| ANIMAL | evidence | Transforming a protease inhibitor into a peptide Guardian: BBI-armed hydrogel beads for Oral delivery of active peptides. | Semaglutide | animal | 2026-07-31 |
| ANIMAL | evidence | AI digital pathology as a key tool providing in-depth understanding of the progression and regression of MASH and fibrosis in male mouse models. | Semaglutide | Liver health · animal | 2026-07-22 |
| ANIMAL | evidence | Preventative semaglutide and tirzepatide treatment does not alter disease progression in the 5xFAD mouse model of Alzheimer's disease. | Semaglutide | Cognition & memory · animal | 2026-07-21 |